angina
Conditions
Interventions
Sponsors
Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Angina pectoris still occurred 3 to 18 months after PCI and was treated and managed according to the Guidelines for Percutaneous Coronary Intervention in China (2016). ? (2) Patients with stable exertive angina who had =2 angina attacks per week in the previous month and whose severity was classified as Canadian Angina severity Scale (CCS) ? - ? were enrolled. ? (3) Patients with ST segment depression or T wave inversion on electrocardiogram, positive motion plate or ischemic changes assessed by SPECT, PET, MRI, CT and other imaging. ? (4) Patients who stopped using drugs for activating blood circulation and removing blood stasis for more than 2 weeks. ? (5) Between 18 and 80 years old, male and female. ? (6) Voluntarily participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Those eligible for revascularization. ? (2) Patients with cardiac function grade ? (NYHA scale, see Appendix 2) or CCS Grade ? (Canadian Angina severity Scale). ? (3) Patients with uncontrolled grade 3 hypertension (systolic blood pressure =180mmHg and/or diastolic blood pressure =110mmHg), severe cardiopulmonary insufficiency, severe arrhythmia, serious primary diseases of liver, kidney and hematopoietic system, or serious diseases affecting their survival (such as tumor) and mental illness. ? (4) Combined with other clinical conditions that may increase the risk of bleeding, such as a history of major organ bleeding in the last six months (such as cerebral hemorrhage, upper gastrointestinal bleeding, etc.), platelet count less than 50×10^9/L, abnormal coagulation function, and oral warfarin anticoagulation treatment, etc. ? (5) abnormal indexes of liver and kidney function (ALT, AST, Scr, BUN 3 times higher than the upper limit of normal reference range). ? (6) Patients with allergic constitution, or food allergy to multiple drugs, or patients known to be allergic to the study drug (including its ingredients). ? (7) those who have a pregnancy plan. ? (8) Breast-feeding women. ? (9) Vulnerable groups: including neurological diseases, cognitive impairment, critically ill patients, minors, pregnant women, etc. ? (10) Patients who participated in other clinical trials within the last 1 month. ? (11) The investigator suggested that there were other patients who were not eligible for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak VO2; | — |
Secondary
| Measure | Time frame |
|---|---|
| METs;MACE;Weber classification of cardiac function;GAD-7;PHQ-9;Start time of ST segment depression or elevation by 1mm;Maximal oxygen uptake without oxygen threshold;VO2/HR;Angina symptom score;Canadian classification of angina severity;Maximum exercise load; | — |
Countries
China
Contacts
Public ContactFu Guosheng
Outcome results
None listed